Details for Patent: 10,821,113

Which drugs does patent 10,821,113 protect, and when does it expire?

Patent 10,821,113 protects TAZVERIK and is included in one NDA.

This patent has fifty-nine patent family members in twenty-four countries.

Summary for Patent: 10,821,113

Title:	Salt form of a human histone methyltransferase EZH2 inhibitor
Abstract:	Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-bip- henyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
Inventor(s):	Kuntz; Kevin Wayne (Woburn, MA), Huang; Kuan-Chun (Andover, MA), Choi; Hyeong Wook (Andover, MA), Sanders; Kristen (Gilmanton, NH), Mathieu; Steven (Andover, MA), Chanda; Arani (Malden, MA), Fang; Francis (Andover, MA)
Assignee:	Epizyme, Inc. (Cambridge, MA) Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	16/270,752
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,821,113

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes			Y	Y

International Family Members for US Patent 10,821,113

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013245878
Australia	2018200168
Brazil	112014025508
Canada	2870005
China	104603130